Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Cross Below Two Hundred Day Moving Average - What's Next?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report)'s stock price passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $2.33 and traded as low as $2.20. Oramed Pharmaceuticals shares last traded at $2.27, with a volume of 118,026 shares traded.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut shares of Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Wednesday, February 19th.

Oramed Pharmaceuticals Stock Performance

The business's fifty day simple moving average is $2.26 and its 200-day simple moving average is $2.32. The firm has a market capitalization of $87.83 million, a PE ratio of 19.55 and a beta of 1.50.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last announced its quarterly earnings results on Thursday, March 27th. The biotechnology company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.04. Sell-side analysts expect that Oramed Pharmaceuticals Inc. will post -0.03 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Oramed Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd lifted its position in Oramed Pharmaceuticals by 59.7% during the third quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company's stock valued at $60,000 after acquiring an additional 9,242 shares during the last quarter. Boothbay Fund Management LLC increased its position in shares of Oramed Pharmaceuticals by 2.0% during the fourth quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company's stock worth $2,045,000 after purchasing an additional 16,857 shares in the last quarter. World Equity Group Inc. purchased a new stake in shares of Oramed Pharmaceuticals during the 4th quarter valued at $48,000. Marquette Asset Management LLC acquired a new stake in shares of Oramed Pharmaceuticals in the 4th quarter worth $81,000. Finally, Dimensional Fund Advisors LP grew its stake in Oramed Pharmaceuticals by 143.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company's stock worth $288,000 after buying an additional 70,190 shares during the last quarter. Institutional investors own 12.73% of the company's stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.